1. Home
  2. PSBD vs FULC Comparison

PSBD vs FULC Comparison

Compare PSBD & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palmer Square Capital BDC Inc.

PSBD

Palmer Square Capital BDC Inc.

N/A

Current Price

$10.30

Market Cap

325.5M

Sector

N/A

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.79

Market Cap

285.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSBD
FULC
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
325.5M
285.4M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
PSBD
FULC
Price
$10.30
$3.79
Analyst Decision
Hold
Buy
Analyst Count
9
8
Target Price
$12.33
$16.38
AVG Volume (30 Days)
68.6K
1.3M
Earning Date
05-06-2026
04-27-2026
Dividend Yield
15.02%
N/A
EPS Growth
N/A
N/A
EPS
1.66
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.34
$2.83
52 Week High
$13.93
$15.74

Technical Indicators

Market Signals
Indicator
PSBD
FULC
Relative Strength Index (RSI) 46.03 45.06
Support Level $10.13 $3.62
Resistance Level $10.24 $3.92
Average True Range (ATR) 0.15 0.07
MACD -0.02 -0.01
Stochastic Oscillator 33.93 18.18

Price Performance

Historical Comparison
PSBD
FULC

About PSBD Palmer Square Capital BDC Inc.

Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: